Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - ... 7 - 8 - 9 - 10 - 11 - 12 - 13 - ...
INVIBES ADVERTSING [BE0974299316/MLINV]   
[02/05/2018]

INVIBES ADVERTSING : INVIBES LANCE SON NOUVEAU FORMAT INVIBES ZOOM, UNE SOLUTION UNIQUE SUR LE MARCHE

Paris, le 2 mai 2018 INVIBES ADVERTISING, AdTech spécialisée dans la publicité digitale intégrée dans les contenus éditoriaux Infeed, annonce le lancement d'Invibes Zoom, une nouvelle étape dans le développement de l'interaction entre l'internaute et la publicité grâce à la mise en valeur du produit par un effet de zoom dans le format publicitaire. Lien démo du produit :... See more
 
RECTICEL [BE0003656676/REC]   
[02/05/2018]

RECTICEL : Capital increase through exercise of warrants

PRESS RELEASE Regulated information Brussels, 02 May 2018 – 07:00 CET Disclosure in accordance with the provisions of the Act of 2 May 2007 CAPITAL INCREASE THROUGH EXERCISE OF WARRANTS Recticel announces that on 27 April 2018 its share capital has been increased following the exercise of i 17,900 warrants of the warrant plan issued on 02 May... See more
 
D'IETEREN [BE0974259880/DIE]   
[30/04/2018]

D'IETEREN : Publication of the annual report 2017

PRESS RELEASE: PUBLICATION OF THE ANNUAL REPORT 2017 Monday 30 April 2018 – 8:00 am CET Publication of the annual report 2017 D’Ieteren announces the publication of its Annual Report 2017. Like... See more
 
UCB [BE0003739530/UCB]   
[27/04/2018]

UCB : UCB Media Room: Cimzia CHMP Psoriasis

UCB Announces Positive CHMP Opinion for CIMZIA® certolizumab pegol in Patients with ModeratetoSevere Plaque PsoriasisCIMZIA® certolizumab pegol Phase 3 psoriasis data demonstrated significant and clinically meaningful improvements in biologicnaïve and previously treated patients, with clinical benefit maintained up to one year1This milestone represents UCB’s entry into immunodermatology,... See more
 
D'IETEREN [BE0974259880/DIE]   
[27/04/2018]